Post-transfusion Hepatitis C Virus Infection and the Hidden Burden of Warm Blood Transfusion in a Resource-Limited Setting: An Analytical Cross-Sectional Study from Mbujimayi, Democratic Republic of Congo
F1000Research · 28.09.2026 · 15 · 1086
DOI: 10.12688/f1000research.183575.2 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift F1000Research, online erschienen am 28.09.2026. Verfasst von Georges Ntambwe und 13 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Blood transfusion remains essential in clinical care, but unsafe transfusion pathways continue to expose recipients to transfusion transmitted infections (TTIs). In the Democratic Republic of the Congo (DRC), more than 90% of transfusions are delivered as warm transfusions, in which blood is released before full infectious marker screening is completed. This study aimed to quantify the additional risk of hepatitis C virus (HCV) transmission associated with this practice in Mbujimayi.
Methods
We conducted a prospective analytical cross-sectional study in four high transfusion-volume hospitals of Mbujimayi from April 8 to 24, 2024. A total of 223 previously transfused individuals (≥ 2 months post-transfusion) were enrolled and stratified into exposed (warm transfusion) and unexposed (cold transfusion) groups. Anti-HCV antibodies were detected using an HCV Scan rapid immunochromatographic assay performed on serum. Crude (cOR) and adjusted (aOR) odds ratios with 95% confidence intervals were estimated using bivariate analyses and multivariable logistic regression in IBM SPSS Statistics version 27, p < 0.05 was considered statistically significant.
Results
The post-transfusion HCV seroprevalence was 4.9% (11/223). After adjustment, two factors remained independently associated with HCV seropositivity: receiving more than one transfusion (aOR = 5.41; 95% CI: 1.22–24.02; p = 0.027) and unemployment (aOR = 4.66; 95% CI: 1.18–18.41; p = 0.028). Among those exposed to warm transfusion, repeated transfusions increased the likelihood of HCV infection tenfold (aOR = 10.03; 95% CI: 3.85–26.16; p < 0.001).
Conclusion
Warm transfusion, the prevailing modality in the DRC, constitutes a significant additional route of HCV transmission. Strengthening voluntary non-remunerated blood donation, ensuring uninterrupted screening for transfusion-transmitted infections, and enforcing systematic use of pre-tested blood units are critical strategies to reduce this preventable burden.
Zitieren
APA
Ntambwe, G., Baloji, D., Muepu, V., Kidinda, W., Kazadi, B., Tshibinkufua, J. R., Tague, C., Nyembo, B. M., Nzaji, M. K., Kabamba, A. M., Mulenga-Cilundika, P., Mjumbe, C. K., Mpanya, A., & Lutumba, P. (2026). Post-transfusion Hepatitis C Virus Infection and the Hidden Burden of Warm Blood Transfusion in a Resource-Limited Setting: An Analytical Cross-Sectional Study from Mbujimayi, Democratic Republic of Congo. F1000Research, 15, 1086. https://doi.org/10.12688/f1000research.183575.2
Vancouver
Ntambwe G, Baloji D, Muepu V, Kidinda W, Kazadi B, Tshibinkufua JR, et al. Post-transfusion Hepatitis C Virus Infection and the Hidden Burden of Warm Blood Transfusion in a Resource-Limited Setting: An Analytical Cross-Sectional Study from Mbujimayi, Democratic Republic of Congo. F1000Research. 2026;15:1086. doi:10.12688/f1000research.183575.2
BibTeX
@article{Ntambwe2026,
author = {Ntambwe, Georges and Baloji, Désiré and Muepu, Venance and Kidinda, William and Kazadi, Benoit and Tshibinkufua, Jean Robert and Tague, Christian and Nyembo, Bertin Mukuna and Nzaji, Michel Kabamba and Kabamba, André Mutombo and Mulenga-Cilundika, Philippe and Mjumbe, Criss Koba and Mpanya, Alain and Lutumba, Pascal},
title = {Post-transfusion Hepatitis C Virus Infection and the Hidden Burden of Warm Blood Transfusion in a Resource-Limited Setting: An Analytical Cross-Sectional Study from Mbujimayi, Democratic Republic of Congo},
journal = {F1000Research},
year = {2026},
volume = {15},
pages = {1086},
doi = {10.12688/f1000research.183575.2}
}
EUVIMED